| CTRI Number |
CTRI/2025/08/093791 [Registered on: 27/08/2025] Trial Registered Prospectively |
| Last Modified On: |
27/08/2025 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Interventional |
|
Type of Study
|
Drug Ayurveda |
| Study Design |
Randomized, Parallel Group, Active Controlled Trial |
|
Public Title of Study
|
A Study to Compare the Efficacy of Rasanjanadya Aschyotana and Olopatadine 0.1% eye drops in the Management of Kaphaja Abhishyanda (Simple Allergic Conjunctivitis) |
|
Scientific Title of Study
|
A Randomized Open Label Controlled Clinical Study to Compare the Efficacy of Rasanjanadya Aschyotana and Olopatadine 0.1% Eye Drops in the Management of Kaphaja Abhishyanda (Simple Allergic Conjunctivitis) |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Prerna |
| Designation |
MS Shalakya Tantra Scholar |
| Affiliation |
Institute for Ayurved Studies and Research SKAU Kurukshetra |
| Address |
Opd no 54 Ground floor Department of Shalakya Tantra
Institute for Ayurved Studies and Research
Shri Krishna AYUSH University Kurukshetra
Haryana
136118
India
Kurukshetra HARYANA 136118 India |
| Phone |
7015247038 |
| Fax |
|
| Email |
jangraprerna85@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Dr Ashu |
| Designation |
Chairperson, PG Department of Shalakya Tantra |
| Affiliation |
Institute for Ayurved Studies and Research SKAU Kurukshetra |
| Address |
Room no 108 1st floor Department of Shalakya Tantra
Institute for Ayurved Studies and Research
Shri Krishna AYUSH University Kurukshetra
Haryana
136118
India
Kurukshetra HARYANA 136118 India |
| Phone |
09416553131 |
| Fax |
|
| Email |
drashukataria@gmail.com |
|
Details of Contact Person Public Query
|
| Name |
Dr Ashu |
| Designation |
Chairperson, PG Department of Shalakya Tantra |
| Affiliation |
Institute for Ayurved Studies and Research SKAU Kurukshetra |
| Address |
Room no 108 1st floor Department of Shalakya Tantra
Institute for Ayurved Studies and Research
Shri Krishna AYUSH University Kurukshetra
Haryana
136118
India
Kurukshetra HARYANA 136118 India |
| Phone |
09416553131 |
| Fax |
|
| Email |
drashukataria@gmail.com |
|
|
Source of Monetary or Material Support
|
| Institute for Ayurved Studies and Research Sector 8 Umri Road Kurukshetra Haryana India 136118 |
|
|
Primary Sponsor
|
| Name |
Institute for Ayurved Studies and Research |
| Address |
Sector 8 Umri Road Kurukshetra Haryana 136118 |
| Type of Sponsor |
Other [Government Ayurvedic College] |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Prerna |
Institute for Ayurved Studies and Research Hospital |
OPD No. 54 Shalakya Netra, Institute for Ayurved Studies and Research Hospital, sector 8 umri road kurukshetra 136118
Kurukshetra
HARYANA Kurukshetra HARYANA |
7015247038
jangraprerna85@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Institutional Ethics Committee Shri Krishna Ayush University Kurukshetra |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition:H108||Other conjunctivitis. Ayurveda Condition: KAPABISHYANDAH, |
|
|
Intervention / Comparator Agent
|
| sno | Intervention/Comparator | Type | Drug-Type | Procedure Name | Details | | 1 | Intervention Arm | Procedure | - | AScyotanam, आश्च्योतनम् | (Procedure Reference: Gada Nigraha, Procedure details: 1.Form Eye drops with 1.Rasanjana 2.Haridra 3.Daruharidra 4.Gokshura 5.Shunthi 6.Madhu.
Patients will be given an Aam Pachana drug Shunthi Churna as purva karma medicine for initial 5 days in dose 1.5 gm BD. After which Aschyotana will be done for 30 days. ) (1) Medicine Name: Rasanjanadya Aschyotana, Reference: Gada Nigraha Tritiya Khanda 3/125, Route: Ocular, Dosage Form: Bindu/ Drops/ Spray (Karna/ Nasa/ Netra/ Mukha), Dose: 2(drops), Frequency: qid, Duration: 30 Days | | 2 | Comparator Arm (Non Ayurveda) | | - | Olopatadine 0.1% eye drops | Olopatadine 0.1% eye drops are Dual action antihistamine and mast cell stabilizer.
•Dose - 1-1 drop twice a day.
•Frequency - 2 times a day.
•Duration -35 Days.
|
|
|
|
Inclusion Criteria
|
| Age From |
16.00 Year(s) |
| Age To |
60.00 Year(s) |
| Gender |
Both |
| Details |
1. Age- 16-60 years
2. Patients with sign and symptoms of Kaphaja Abhishyanda (Simple Allergic Conjunctivitis) will be selected irrespective of Sex, Religion and Profession.
3. Patients those are fit for Aschyotana Karma according to Ayurveda text23.
4. Patient willing to participate and able to provide signed informed consent.
|
|
| ExclusionCriteria |
| Details |
1. Age group less than 16 years and more than 60 years.
2. The patient having any systemic illness, like - Diabetes mellitus, Hypertension, Tuberculosis, etc.
3. Patients suffering from other type of Conjunctivitis, Marginal Corneal Ulcer, Dacryocystitis and other ocular manifestations.
4. Patients with alcohol, opioids / drug addiction and using any other systemic drugs which may alter the result of study.
5. Patients having genetic predisposition to allergy.
6. Pregnant and lactating mothers.
|
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
|
Method of Concealment
|
On-site computer system |
|
Blinding/Masking
|
Open Label |
|
Primary Outcome
|
| Outcome |
TimePoints |
| 1. Change in scoring pattern of sign and symptoms of Kaphaja Abhishyanda (Simple Allergic Conjunctivitis). |
35th day |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| NIL |
NIL |
|
|
Target Sample Size
|
Total Sample Size="44" Sample Size from India="44"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
Phase 2 |
|
Date of First Enrollment (India)
|
01/12/2025 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="1" Months="6" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Yet Recruiting |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
Kaphaja Abhishayanda is characterized by Ushnaabhinanda (Want of warmth), Guruta (heaviness of lids), Akhshishopha (swelling of eyes), Kandu (itching), Updeha (stickiness in eyes), Atisitata (Excessive coldness), Sravamuhurpichila (recurrent excessive slimy discharge from eye); so, on the basis of signs and symptoms Kaphaja Abhishyanda can be correlated with Simple Allergic Conjunctivitis. Simple Allergic Conjunctivitis, is a type-1 immediate hypersensitivity reaction mediated by IgE and subsequent mast cell activation, following exposure of ocular surface to airborne allergens.Ayurveda offers an alternative and holistic approach to manage such conditions using herbal formulations that aim at correcting the doshic imbalance while providing symptomatic relief. Rasanjanadya Aschyotana, an Ayurvedic eye drop formulation comprising ingredients like Rasanjana, Haridra, and Madhu is described in classical texts for Kaphaja Abhishyanda.This study is designed to evaluate and compare the therapeutic efficacy of Rasanjanadya Aschyotana with that of Olopatadine 0.1% eye drops (Dual action antihistamine and mast cell stabilizer) in patients suffering from Kaphaja Abhishyanda (Simple Allergic Conjunctivitis). By employing a randomized open-label controlled clinical trial design, this research aims to generate scientific evidence for the effectiveness of Rasanjanadya Aschyotana, potentially establishing it as a viable, natural alternative to modern pharmacotherapy. |